Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation

The 1-year graft failure-free survival was 90%, which is clinically meaningful and supports full marketing authorization submission Idefirix was generally well tolerated with a safety profile consistent with previous clinical trial experience Submission to EMA for conversion to full...